<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-44801</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Induced Cell Death and/or Induced Cell Killing for HIV Cure (consortium agreement for PPS projects)</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Current HIV Cure intervention strategies largely target host factors for manipulation of viral expression or immune clearance. Therefore, patient response to intervention strategies (as in cancer treatment) will be variable and specific to the particular patient. Here we willestablish an ex vivo innovative platform derived from the patient&apos;s own latently infected cells and autologous immune system to develop tools, characterize and quantitate reservoir size, activity aswell as immune clearance of infected cells (WP1). We will use the  ongoing HIV patient cohorts that are coordinated by the participating UMCs where material is available from approximately 5,000 patients at various stages of disease. We will use our primary patient-derived HIV latency platforms to test an innovative pipeline of latency reversal agents combinations exhibiting superior potency with limited associated cytotoxicity and determine optimal combinations of LRA (cLRA)s. We will then apply different approaches to trigger and gain a deeper understanding of mechanisms that can be exploited to eliminate HIV-infected CD4+ T cells after they are stimulated to emerge out of latency. We distinguish two major modes of elimination of such cells. One is the induction of infected cell death (ICD), which we explore in WP2 by exploiting cell intrinsic mechanisms, which together with the cLRA-stimulated transcriptional activation of HIV within the CD4+ T cells result in cell apoptosis. These include small molecule driven blockage of HIV translation and modulation of danger sensing pathways that could trigger apoptosis of infected cells. In WP 3 (infected cell killing or ICK) we will investigate the use of the immune response to kill such HIV reexpressing CD4+ T cells. Here we will look at efficacy of combining LRAs with inhibitory receptor blockade and augmenting CTL activity. In addition, we will redirect CD8 T cell killing to the LRA-treated reservoir using bi- and tri-specific antibodies.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2019-11-01" type="2"></activity-date>
  <activity-date iso-date="2022-09-30" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C42" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2019-11-01"></period-start>
   <period-end iso-date="2022-09-30"></period-end>
   <value currency="EUR" value-date="2019-11-01">250000</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2020-12-17"></transaction-date>
   <value currency="EUR" value-date="2020-12-17">13490</value>
   <description>
    <narrative xml:lang="EN">Cash; toegekend in 2019, budget 2019</narrative>
   </description>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Viroscience</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-12-17"></transaction-date>
   <value currency="EUR" value-date="2020-12-17">12141</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Viroscience</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-17"></transaction-date>
   <value currency="EUR" value-date="2020-12-17">12141</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Viroscience</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-25801" type="1"></related-activity>
 </iati-activity>
</iati-activities>
